retatrutide type 2 diabetes trial results Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 New clinical trial results show

Why it matters: The growth of weight loss drugs opens the door for wellness and beauty brands created specifically for the side effects some users experience, such as loss in skin elasticity

The comments are open

Current access in Canada requires obtaining the medication through research peptide suppliers who sell for non-human research purposes

Some men breathe a sigh of relief watching that persistent fat disappear, yet others may be concerned about sagging skin or shifted body contours, particularly following significant weight loss

2017;312(5):R797R805

Correspondent Tracy Smith talks with experts who say the drugs might prove useful in treating other diseases associated with obesity (including cancer)